Evofem Biosciences, Inc.
EVFMDrugs in Pipeline
4
Phase 3 Programs
4
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How EVFM's past catalysts played out
AMPHORA
Contraception
Conceptrol
Contraception
EVO100
Sexually Transmitted Diseases
LIPO-202
Central Abdominal Bulging
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
AMPHORA | Phase 3 | Contraception | - | - |
Conceptrol | Phase 3 | Contraception | - | - |
EVO100 | Phase 3 | Sexually Transmitted Diseases | - | - |
LIPO-202 | Phase 3 | Central Abdominal Bulging | - | - |
Frequently asked questions
What is in Evofem Biosciences, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Evofem Biosciences, Inc.'s (EVFM) pipeline across Phase 3. Its lead program is AMPHORA (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Evofem Biosciences, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Evofem Biosciences, Inc. (EVFM) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track EVFM biotech catalysts?→
Add EVFM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Evofem Biosciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.